Weber K S, Strassburger K, Pacini G, Nowotny B, Müssig K, Szendroedi J, Herder C, Roden M
Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf.
German Center for Diabetes Research (DZD), München-Neuherberg.
Diabet Med. 2017 Feb;34(2):239-244. doi: 10.1111/dme.13278. Epub 2016 Nov 17.
To examine the hypothesis that changes in serum adiponectin concentration inversely relate to changes in glucose tolerance and β-cell function already during the early stage of disease progression in recently diagnosed Type 1 and Type 2 diabetes mellitus.
Participants in the prospective observational German Diabetes Study (Type 2 diabetes, n = 94; Type 1 diabetes, n = 42) underwent i.v. glucose tolerance and glucagon stimulation testing to assess pre-hepatic β-cell function, glucose tolerance index and C-peptide secretion within the first year of diabetes diagnosis and 2 years later. Associations of changes in serum concentrations of total adiponectin, high-molecular-weight adiponectin and their ratio with changes in the aforementioned metabolic variables were calculated using linear regression.
Among people with Type 2 diabetes, 2-year increases in high-molecular-weight adiponectin and in high-molecular-weight/total adiponectin ratio were associated with decreases in glucose tolerance index of 0.1%/min (P = 0.020) and 0.8%/min (P = 0.013), respectively. Increases in high-molecular-weight/total adiponectin ratio were related to decreases in acute C-peptide secretion of 54.6% (P = 0.020). Among people with Type 1 diabetes, 2-year increases in total adiponectin were associated with 2-year decreases in acute C-peptide secretion of 56.2% (P = 0.035).
Increases in adiponectin concentrations in the first 2 years after diagnosis were related to a worsening of acute insulin secretion and glucose tolerance index in Type 1 and Type 2 diabetes. (Clinical Trials Registry no.: NCT01055093).
检验如下假设:在新诊断的1型和2型糖尿病疾病进展的早期阶段,血清脂联素浓度的变化与葡萄糖耐量及β细胞功能的变化呈负相关。
前瞻性观察性德国糖尿病研究的参与者(2型糖尿病,n = 94;1型糖尿病,n = 42)在糖尿病诊断后的第一年及2年后接受静脉葡萄糖耐量和胰高血糖素刺激试验,以评估肝前β细胞功能、葡萄糖耐量指数和C肽分泌。使用线性回归计算总脂联素、高分子量脂联素及其比值的血清浓度变化与上述代谢变量变化之间的关联。
在2型糖尿病患者中,高分子量脂联素和高分子量/总脂联素比值的2年增加分别与葡萄糖耐量指数每分钟降低0.1%(P = 0.020)和0.8%(P = 0.013)相关。高分子量/总脂联素比值的增加与急性C肽分泌降低54.6%相关(P = 0.020)。在1型糖尿病患者中,总脂联素的2年增加与急性C肽分泌2年降低56.2%相关(P = 0.035)。
诊断后前2年脂联素浓度的增加与1型和2型糖尿病急性胰岛素分泌和葡萄糖耐量指数的恶化相关。(临床试验注册号:NCT01055093)